Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTC Cream
- Development stage
- Phase 4
- Lead developer
- Andros Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LTC Cream is a topical anesthetic formulation developed by Andros Pharmaceuticals, containing a combination of the amide-type local anesthetic lidocaine and the ester-type local anesthetic tetracaine. Categorized as a "super generic" by the developer, it is approved for use in topical anesthesia. The product functions by reversibly blocking voltage-gated sodium channels in the neuronal membrane. This action inhibits the ionic flux required for the initiation and conduction of nerve impulses, thereby providing localized anesthesia to the skin. LTC Cream is typically utilized to provide rapid and prolonged numbing for dermatological procedures, minor medical interventions, or cosmetic treatments.
- Brand names
- LTC Cream
- Other names
- lidocaine + tetracaine cream
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on LTC Cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTC Cream.